Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Trial of a Mutated gp100 Melanoma Peptide (g209-217(210M) With Hight Dose Interleukin-2 (IL-2) in HLA-A2.1+Patients With Metastatic Melanoma

NCT00003568 is registered in ClinicalTrials.gov with University of Illinois at Chicago as lead sponsor.

NCT NCT00003568
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003568 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Trial of a Mutated gp100 Melanoma Peptide (g209-217(210M) With Hight Dose Interleukin-2 (IL-2) in HLA-A2.1+Patients With Metastatic Melanoma
Lead sponsor
University of Illinois at Chicago
Phase
Phase 2
Overall status
Completed
Start date
November 30, 1998
Completion date
December 31, 2005
Enrollment
Not reported
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma (skin)